Cancer Research The Future of Cancer Research: Science and Patient Impact Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kozin, S. V.
Right arrow Articles by Suit, H. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kozin, S. V.
Right arrow Articles by Suit, H. D.
[Cancer Research 61, 39-44, January 1, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Vascular Endothelial Growth Factor Receptor-2-blocking Antibody Potentiates Radiation-induced Long-Term Control of Human Tumor Xenografts1

Sergey V. Kozin, Yves Boucher, Daniel J. Hicklin, Peter Bohlen, Rakesh K. Jain2 and Herman D. Suit

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114 [S. V. K., Y. B., R. K. J., H. D. S.], and Department of Immunology, ImClone Systems, Incorporated, New York, New York 10014 [D. J. H., P. B.].

Antiangiogenic therapy can enhance radiation-induced tumor growth inhibition. However, the effects of combined antiangiogenic and radiation therapy on long-term tumor control and normal tissue response have not been reported. We treated mice bearing two different human tumor xenografts with anti-vascular endothelial growth factor receptor-2 antibody (DC101) and five dose fractions of local radiation and followed them for at least 6 months. DC101 significantly decreased the dose of radiation necessary to control 50% of tumors locally. The decrease was 1.7- and 1.3-fold for the moderately radiosensitive small cell lung carcinoma 54A and the highly radioresistant glioblastoma multiforme U87, respectively. In contrast to tumors, no increase in skin radiation reaction by the antibody was detected. Surprisingly, 44% of mice bearing 54A tumor developed clear ascites after DC101 treatment at its highest dose; this was fatal to 20% of mice. This adverse effect was seen only in mice that received whole-body irradiation 1 day before tumor implantation. The encouraging results on two human tumor xenografts suggest that vascular endothelial growth factor receptor-2 blockade merits further investigation to assess its potential as an enhancer of radiation therapy in the clinic.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
K. Takata, K.-i. Morishige, T. Takahashi, K. Hashimoto, S. Tsutsumi, L. Yin, T. Ohta, J. Kawagoe, K. Takahashi, and H. Kurachi
Fasudil-induced hypoxia-inducible factor-1{alpha} degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells
Mol. Cancer Ther., June 1, 2008; 7(6): 1551 - 1561.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Y. Seiwert, D. J. Haraf, E. E.W. Cohen, K. Stenson, M. E. Witt, A. Dekker, M. Kocherginsky, R. R. Weichselbaum, H. X. Chen, and E. E. Vokes
Phase I Study of Bevacizumab Added to Fluorouracil- and Hydroxyurea-Based Concomitant Chemoradiotherapy for Poor-Prognosis Head and Neck Cancer
J. Clin. Oncol., April 1, 2008; 26(10): 1732 - 1741.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Youssoufian, D. J. Hicklin, and E. K. Rowinsky
Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy
Clin. Cancer Res., September 15, 2007; 13(18): 5544s - 5548s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Duda, R. K. Jain, and C. G. Willett
Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers
J. Clin. Oncol., September 10, 2007; 25(26): 4033 - 4042.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Oehler-Janne, W. Jochum, O. Riesterer, A. Broggini-Tenzer, G. Caravatti, V. Vuong, and M. Pruschy
Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models
Mol. Cancer Ther., September 1, 2007; 6(9): 2496 - 2504.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. V. Kozin, F. Winkler, I. Garkavtsev, D. J. Hicklin, R. K. Jain, and Y. Boucher
Human Tumor Xenografts Recurring after Radiotherapy Are More Sensitive to Anti-Vascular Endothelial Growth Factor Receptor-2 Treatment than Treatment-Naive Tumors
Cancer Res., June 1, 2007; 67(11): 5076 - 5082.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Ogawa, Y. Boucher, S. Kashiwagi, D. Fukumura, D. Chen, and L. E. Gerweck
Influence of Tumor Cell and Stroma Sensitivity on Tumor Response to Radiation
Cancer Res., May 1, 2007; 67(9): 4016 - 4021.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Abdelrahim, C. H. Baker, J. L. Abbruzzese, D. Sheikh-Hamad, S. Liu, S. D. Cho, K. Yoon, and S. Safe
Regulation of Vascular Endothelial Growth Factor Receptor-1 Expression by Specificity Proteins 1, 3, and 4 in Pancreatic Cancer Cells
Cancer Res., April 1, 2007; 67(7): 3286 - 3294.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Senan and E. F. Smit
Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy
Oncologist, April 1, 2007; 12(4): 465 - 477.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Tabernero
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents
Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. J. Williams, B. A. Telfer, A. M. Shannon, M. Babur, I. J. Stratford, and S. R. Wedge
Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit
Mol. Cancer Ther., February 1, 2007; 6(2): 599 - 606.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. Horsman and D. W. Siemann
Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies
Cancer Res., December 15, 2006; 66(24): 11520 - 11539.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Sathornsumetee, A. B. Hjelmeland, S. T. Keir, R. E. McLendon, D. Batt, T. Ramsey, N. Yusuff, B.K. A. Rasheed, M. W. Kieran, A. Laforme, et al.
AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma.
Cancer Res., September 1, 2006; 66(17): 8722 - 8730.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Riesterer, M. Honer, W. Jochum, C. Oehler, S. Ametamey, and M. Pruschy
Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment.
Clin. Cancer Res., June 1, 2006; 12(11): 3518 - 3524.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. H. Crane, L. M. Ellis, J. L. Abbruzzese, C. Amos, H. Q. Xiong, L. Ho, D. B. Evans, E. P. Tamm, C. Ng, P. W.T. Pisters, et al.
Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer
J. Clin. Oncol., March 1, 2006; 24(7): 1145 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Abdollahi, D. W. Griggs, H. Zieher, A. Roth, K. E. Lipson, R. Saffrich, H.-J. Grone, D. E. Hallahan, R. A. Reisfeld, J. Debus, et al.
Inhibition of {alpha}v{beta}3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy
Clin. Cancer Res., September 1, 2005; 11(17): 6270 - 6279.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. P. Tew, D. P. Kelsen, and D. H. Ilson
Targeted Therapies for Esophageal Cancer
Oncologist, September 1, 2005; 10(8): 590 - 601.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Zips, W. Eicheler, P. Geyer, F. Hessel, A. Dorfler, H. D. Thames, M. Haberey, and M. Baumann
Enhanced Susceptibility of Irradiated Tumor Vessels to Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibition
Cancer Res., June 15, 2005; 65(12): 5374 - 5379.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Podar and K. C. Anderson
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Blood, February 15, 2005; 105(4): 1383 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Hicklin and L. M. Ellis
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
J. Clin. Oncol., February 10, 2005; 23(5): 1011 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Ansiaux, C. Baudelet, B. F. Jordan, N. Beghein, P. Sonveaux, J. De Wever, P. Martinive, V. Gregoire, O. Feron, and B. Gallez
Thalidomide Radiosensitizes Tumors through Early Changes in the Tumor Microenvironment
Clin. Cancer Res., January 15, 2005; 11(2): 743 - 750.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. S. Wang, J. Teruya-Feldstein, Y. Wu, Z. Zhu, D. J. Hicklin, and M. A. S. Moore
Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo
Blood, November 1, 2004; 104(9): 2893 - 2902.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. M. Fenton, S. F. Paoni, and I. Ding
Pathophysiological Effects of Vascular Endothelial Growth Factor Receptor-2-Blocking Antibody plus Fractionated Radiotherapy on Murine Mammary Tumors
Cancer Res., August 15, 2004; 64(16): 5712 - 5719.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
N. Ferrara
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Endocr. Rev., August 1, 2004; 25(4): 581 - 611.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. H. Crane and D. J. Sargent
Substitution of Oral Fluoropyrimidines for Infusional Fluorouracil With Radiotherapy: How Much Data Do We Need?
J. Clin. Oncol., August 1, 2004; 22(15): 2978 - 2981.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
R. T. Tong, Y. Boucher, S. V. Kozin, F. Winkler, D. J. Hicklin, and R. K. Jain
Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors
Cancer Res., June 1, 2004; 64(11): 3731 - 3736.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Marzola, A. Degrassi, L. Calderan, P. Farace, C. Crescimanno, E. Nicolato, A. Giusti, E. Pesenti, A. Terron, A. Sbarbati, et al.
In Vivo Assessment of Antiangiogenic Activity of SU6668 in an Experimental Colon Carcinoma Model
Clin. Cancer Res., January 15, 2004; 10(2): 739 - 750.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
R. Kolesnick and Z. Fuks
Response to Comments on "Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis"
Science, December 12, 2003; 302(5652): 1894e - 1894e.
[Full Text] [PDF]

Home page
 Circ. Res.Home page
D. Fukumura, A. Ushiyama, D. G. Duda, L. Xu, J. Tam, V. Krishna, K. Chatterjee, I. Garkavtsev, and R. K. Jain
Paracrine Regulation of Angiogenesis and Adipocyte Differentiation During In Vivo Adipogenesis
Circ. Res., October 31, 2003; 93 (9): e88 - e97.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Schueneman, E. Himmelfarb, L. Geng, J. Tan, E. Donnelly, D. Mendel, G. McMahon, and D. E. Hallahan
SU11248 Maintenance Therapy Prevents Tumor Regrowth after Fractionated Irradiation of Murine Tumor Models
Cancer Res., July 15, 2003; 63(14): 4009 - 4016.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. K. Rofstad, K. Henriksen, K. Galappathi, and B. Mathiesen
Antiangiogenic Treatment with Thrombospondin-1 Enhances Primary Tumor Radiation Response and Prevents Growth of Dormant Pulmonary Micrometastases after Curative Radiation Therapy in Human Melanoma Xenografts
Cancer Res., July 15, 2003; 63(14): 4055 - 4061.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu
Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents
J. Clin. Oncol., July 15, 2003; 21(14): 2760 - 2776.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Abdollahi, K. E. Lipson, X. Han, R. Krempien, T. Trinh, K. J. Weber, P. Hahnfeldt, L. Hlatky, J. Debus, A. R. Howlett, et al.
SU5416 and SU6668 Attenuate the Angiogenic Effects of Radiation-induced Tumor Cell Growth Factor Production and Amplify the Direct Anti-endothelial Action of Radiation in Vitro
Cancer Res., July 1, 2003; 63(13): 3755 - 3763.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Wachsberger, R. Burd, and A. P. Dicker
Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interaction
Clin. Cancer Res., June 1, 2003; 9(6): 1957 - 1971.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
M. Garcia-Barros, F. Paris, C. Cordon-Cardo, D. Lyden, S. Rafii, A. Haimovitz-Friedman, Z. Fuks, and R. Kolesnick
Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis
Science, May 16, 2003; 300(5622): 1155 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Posey, T. C. Ng, B. Yang, M. B. Khazaeli, M. D. Carpenter, F. Fox, M. Needle, H. Waksal, and A. F. LoBuglio
A Phase I Study of Anti-Kinase Insert Domain-containing Receptor Antibody, IMC-1C11, in Patients with Liver Metastases from Colorectal Carcinoma
Clin. Cancer Res., April 1, 2003; 9(4): 1323 - 1332.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Sonveaux, A. Brouet, X. Havaux, V. Gregoire, C. Dessy, J.-L. Balligand, and O. Feron
Irradiation-induced Angiogenesis through the Up-Regulation of the Nitric Oxide Pathway: Implications for Tumor Radiotherapy
Cancer Res., March 1, 2003; 63(5): 1012 - 1019.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Izumi, E. di Tomaso, A. Hooper, P. Huang, J. Huber, D. J. Hicklin, D. Fukumura, R. K. Jain, and H. D. Suit
Responses to Antiangiogenesis Treatment of Spontaneous Autochthonous Tumors and Their Isografts
Cancer Res., February 15, 2003; 63(4): 747 - 751.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Gomez, C. Simon, J. Remohi, and A. Pellicer
Vascular Endothelial Growth Factor Receptor-2 Activation Induces Vascular Permeability in Hyperstimulated Rats, and this Effect Is Prevented by Receptor Blockade
Endocrinology, November 1, 2002; 143(11): 4339 - 4348.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. A. Burke, S. J. DeNardo, L. A. Miers, K. R. Lamborn, S. Matzku, and G. L. DeNardo
Cilengitide Targeting of {alpha}v{beta}3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts
Cancer Res., August 1, 2002; 62(15): 4263 - 4272.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. E. Stephen, L. A. Pearsall, B. P. Christian, P. K. Donahoe, J. P. Vacanti, and D. T. MacLaughlin
Highly Purified Mullerian Inhibiting Substance Inhibits Human Ovarian Cancer in Vivo
Clin. Cancer Res., August 1, 2002; 8(8): 2640 - 2646.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. M. Veenendaal, H. Jin, S. Ran, L. Cheung, N. Navone, J. W. Marks, J. Waltenberger, P. Thorpe, and M. G. Rosenblum
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors
PNAS, June 11, 2002; 99(12): 7866 - 7871.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Zhang, D. Yu, D. J. Hicklin, J. A. F. Hannay, L. M. Ellis, and R. E. Pollock
Combined Anti-Fetal Liver Kinase 1 Monoclonal Antibody and Continuous Low-Dose Doxorubicin Inhibits Angiogenesis and Growth of Human Soft Tissue Sarcoma Xenografts by Induction of Endothelial Cell Apoptosis
Cancer Res., April 1, 2002; 62(7): 2034 - 2042.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. J. Griffin, B. W. Williams, R. Wild, J. M. Cherrington, H. Park, and C. W. Song
Simultaneous Inhibition of the Receptor Kinase Activity of Vascular Endothelial, Fibroblast, and Platelet-derived Growth Factors Suppresses Tumor Growth and Enhances Tumor Radiation Response
Cancer Res., March 1, 2002; 62(6): 1702 - 1706.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. L. Reimer, N. Agata, J. G. Tammam, M. Bamberg, W. M. Dickerson, G. D. Kamphaus, S. L. Rook, M. Milhollen, R. Fram, R. Kalluri, et al.
Antineoplastic Effects of Chemotherapeutic Agents Are Potentiated by NM-3, an Inhibitor of Angiogenesis
Cancer Res., February 1, 2002; 62(3): 789 - 795.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Takahashi, A. Haba, F. Matsuno, and B. K. Seon
Antiangiogenic Therapy of Established Tumors in Human Skin/Severe Combined Immunodeficiency Mouse Chimeras by Anti-Endoglin (CD105) Monoclonal Antibodies, and Synergy between Anti-Endoglin Antibody and Cyclophosphamide
Cancer Res., November 1, 2001; 61(21): 7846 - 7854.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. V. Kozin, P. Shkarin, and L. E. Gerweck
The Cell Transmembrane pH Gradient in Tumors Enhances Cytotoxicity of Specific Weak Acid Chemotherapeutics
Cancer Res., June 1, 2001; 61(12): 4740 - 4743.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.